

# Genzyme-Sanofi integration: Transfer of business units

## Transfer of Haematology-Oncology, Renal-Endocrinology, and Biosurgery businesses

**Guildford – Tuesday 24 January:** Last year Genzyme Corporation was acquired by the global healthcare company Sanofi, with the merger completing at a corporate level in April 2011. In the UK & Ireland, Genzyme formally became part of the Sanofi Group from January 2012, bringing a number of changes with respect to therapeutic business units.

Beyond rare diseases, Genzyme has built strong haematology-oncology, renal-endocrinology, and biosurgery businesses that include market-leading products that provide significant benefit to patients. As a result of the merger with Sanofi these three franchises transfer across and are fully integrated within Sanofi Pharmaceuticals Operations.

From the beginning of January, Sanofi has been managing these transferred therapeutic areas and the portfolio of medicines within, providing medical and regulatory support.

The Personalised Genetic Health (PGH) and Multiple Sclerosis (MS) businesses remain within the Genzyme operating unit. Sanofi's experimental MS drug *teriflunomide* transfers across to the Genzyme MS franchise.

#### - Ends -

#### **About Sanofi**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). <a href="https://www.sanofi.com">www.sanofi.com</a>

### About Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme's portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world's largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

### www.genzvme.com

**Contact: Sanofi Media Relations** 

lan Weatherhead Tel: 01483 554274 Mobile: 07984 685557

E-mail: ian.weatherhead@sanofi.com

Date of Preparation: January 2012 GBIE.SAA.12.01.10